tafamidis meglumine

US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy

New Delhi, January 16, 2019: Pfizer Inc. announced today that the US Food and Drug Administration (FDA) accepted for filing…

6 years ago